US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DAMORA THERAPEUT

28.10

+1.264.69%

Post-market: 28.100.00000.00%19:30 EDT

Volume:525.41K

Turnover:14.69M

Market Cap:1.73B

PE:-2.85

High:28.53

Open:27.32

Low:26.87

Close:26.84

52wk High:38.33

52wk Low:2.53

Shares:61.55M

Float Shares:47.65M

Volume Ratio:1.13

T/O Rate:1.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-9.8764

EPS(LYR):-153.9532

ROE:-99.74%

ROA:-21.61%

PB:4.48

PE(LYR):-0.18

Loading ...

Overview Company News Filings

Damora Therapeutics files Form 3 for CEO, Director Jennifer Jarrett

Damora grants CEO Jennifer Jarrett 1.5 million stock options, 500,000 RSUs as inducement award

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics files initial beneficial ownership statement; director Michael Landsittel reports no securities beneficially owned

Stock Track | Damora Therapeutics Soars 7.88% Intraday on Leadership Shakeup with New CEO and Board Appointments

Stock Track | Damora Therapeutics Plunges 8.93% in Pre-Market on Leadership Shakeup

Damora Therapeutics appoints Jennifer Jarrett as CEO

Press Release: Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors

Damora Therapeutics FY2025 net loss widened to USD 209.84 million as R&D expenses rose more than tripled to USD 26.88 million

Press Release: Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Galecto Inc - Changes Name to Damora Therapeutics; to Trade as "Dmra" on Nasdaq March 10, 2026

THOMSON REUTERS

Galecto Inc - Damora to Submit Ind or Cta for Dmr-001 in Mid-2026; Proof-of-Concept Datasets Expected Mid-2027

THOMSON REUTERS

Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/DMRA/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"DMRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMRA\",,,,,undefined,":{"symbol":"DMRA","market":"US","secType":"STK","nameCN":"DAMORA THERAPEUT","latestPrice":28.1,"timestamp":1789156800000,"preClose":26.84,"halted":0,"volume":525410,"hourTrading":{"tag":"盘后","latestPrice":28.1,"preClose":28.1,"latestTime":"19:30 EDT","volume":10753,"amount":302160.02,"timestamp":1789169408731,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.04694485842026831,"floatShares":47648701,"shares":61553200,"eps":-9.876431,"marketStatus":"Not Yet Opened","change":1.26,"latestTime":"09-11 16:00:00 EDT","open":27.32,"high":28.53,"low":26.87,"amount":14690405.8049,"amplitude":0.061848,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.876431,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":0,"adr":0,"listingDate":1603944000000,"exchange":"NASDAQ","adjPreClose":26.84,"postHourTrading":{"tag":"盘后","latestPrice":28.1,"preClose":28.1,"latestTime":"19:30 EDT","volume":10753,"amount":302160.02,"timestamp":1789169408731,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1304901638039173},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMRA\",,,,,undefined,":{"symbol":"DMRA","floatShares":47648701,"roa":"-21.61%","roe":"-99.74%","lyrEps":-153.953213,"volumeRatio":1.1304901638039173,"shares":61553200,"dividePrice":0,"high":28.53,"amplitude":0.061848,"preClose":26.84,"low":26.87,"week52Low":2.53,"pbRate":"4.48","week52High":38.3251,"institutionHeld":0,"latestPrice":28.1,"eps":-9.876431,"divideRate":0,"volume":525410,"delay":0,"ttmEps":-9.876431,"open":27.32,"prevYearClose":23.01,"prevWeekClose":30.06,"prevMonthClose":28.18,"prevQuarterClose":26.01,"fiveDayClose":28,"twentyDayClose":30.73,"sixtyDayClose":20.59},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DMRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-12","symbol":"DMRA","fiscalQuarterEnding":"2026/03","expectedEps":-0.21,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.62},{"market":"US","date":"2026-03-19","symbol":"DMRA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773892800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-06","symbol":"DMRA","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-2.36},{"market":"US","date":"2025-08-05","symbol":"DMRA","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-2.6},{"market":"US","date":"2025-05-08","symbol":"DMRA","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-1.92}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DMRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DMRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":10,"updateTime":1785124800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DMRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DMRA","date":"2026-09-11","current":-2.845157,"percent":0.81746,"low":-100.260711,"twenty":-7.706597,"median":-7.187671,"eighty":-6.346489,"high":-5.207587,"avg":-12.339462,"sd":20.848416,"marketCap":1656981329},"quantilePoints":[{"date":"2026-03-13","current":-100.260711,"twenty":-100.260711,"median":-100.260711,"eighty":-98.29884,"marketCap":1588530698},{"date":"2026-03-20","current":-72.999835,"twenty":-100.199878,"median":-95.983376,"eighty":-84.763454,"marketCap":1156609382},{"date":"2026-03-27","current":-7.36551,"twenty":-98.861547,"median":-80.41388,"eighty":-7.003988,"marketCap":1545571323},{"date":"2026-04-02","current":-7.207452,"twenty":-96.587906,"median":-7.443103,"eighty":-7.019507,"marketCap":1512404556},{"date":"2026-04-10","current":-7.670132,"twenty":-94.238224,"median":-7.361199,"eighty":-7.021806,"marketCap":1609492728},{"date":"2026-04-17","current":-7.759219,"twenty":-89.113027,"median":-7.443103,"eighty":-7.088477,"marketCap":1628186724},{"date":"2026-04-24","current":-7.305161,"twenty":-78.931071,"median":-7.519258,"eighty":-7.200555,"marketCap":1532907649},{"date":"2026-05-01","current":-7.374132,"twenty":-59.951712,"median":-7.420112,"eighty":-7.071235,"marketCap":1547380419},{"date":"2026-05-08","current":-7.181588,"twenty":-7.748873,"median":-7.369821,"eighty":-7.098823,"marketCap":1506977267},{"date":"2026-05-15","current":-6.125513,"twenty":-7.702318,"median":-7.328151,"eighty":-6.979849,"marketCap":1440040702},{"date":"2026-05-22","current":-6.376895,"twenty":-7.679328,"median":-7.296539,"eighty":-6.874668,"marketCap":1499137850},{"date":"2026-05-29","current":-6.50384,"twenty":-7.670132,"median":-7.208889,"eighty":-6.624282,"marketCap":1528981338},{"date":"2026-06-05","current":-5.841412,"twenty":-7.647141,"median":-7.181588,"eighty":-6.506459,"marketCap":1373251758},{"date":"2026-06-12","current":-5.592674,"twenty":-7.644267,"median":-7.103996,"eighty":-6.310202,"marketCap":1314776223},{"date":"2026-06-18","current":-5.608384,"twenty":-7.605184,"median":-7.036462,"eighty":-6.158347,"marketCap":1318469415},{"date":"2026-06-26","current":-5.909488,"twenty":-7.595413,"median":-6.974676,"eighty":-5.98699,"marketCap":1389255588},{"date":"2026-07-02","current":-7.092956,"twenty":-7.5092,"median":-6.96318,"eighty":-6.007936,"marketCap":1667476025},{"date":"2026-07-10","current":-8.059107,"twenty":-7.645417,"median":-7.006288,"eighty":-6.078901,"marketCap":1894607311},{"date":"2026-07-17","current":-7.917719,"twenty":-7.67473,"median":-7.092956,"eighty":-6.150138,"marketCap":1861368586},{"date":"2026-07-24","current":-7.637561,"twenty":-7.776537,"median":-7.12986,"eighty":-6.183485,"marketCap":1795506668},{"date":"2026-07-31","current":-7.648035,"twenty":-7.738833,"median":-7.190209,"eighty":-6.195797,"marketCap":1797968796},{"date":"2026-08-07","current":-7.82346,"twenty":-7.815082,"median":-7.208161,"eighty":-6.219919,"marketCap":1839209436},{"date":"2026-08-14","current":-7.218207,"twenty":-7.815082,"median":-7.209243,"eighty":-6.276357,"marketCap":1897132498},{"date":"2026-08-21","current":-7.119553,"twenty":-7.785196,"median":-7.218207,"eighty":-6.321676,"marketCap":1871203580},{"date":"2026-08-28","current":-7.187671,"twenty":-7.738833,"median":-7.209243,"eighty":-6.354091,"marketCap":1889106881},{"date":"2026-09-04","current":-6.576954,"twenty":-7.707949,"median":-7.198831,"eighty":-6.380999,"marketCap":1728594532},{"date":"2026-09-11","current":-6.30448,"twenty":-7.706597,"median":-7.187671,"eighty":-6.346489,"marketCap":1656981329}],"updateTime":1789371200427},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DMRA\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2624010544","title":"Damora Therapeutics files Form 3 for CEO, Director Jennifer Jarrett","url":"https://stock-news.laohu8.com/highlight/detail?id=2624010544","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624010544?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:25","pubTimestamp":1775078721,"startTime":"0","endTime":"0","summary":"Damora Therapeutics filed a Form 3 initial beneficial ownership statement for Jennifer Jarrett, president, chief executive officer, director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDLbtdbGs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623431795","title":"Damora grants CEO Jennifer Jarrett 1.5 million stock options, 500,000 RSUs as inducement award","url":"https://stock-news.laohu8.com/highlight/detail?id=2623431795","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623431795?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:12","pubTimestamp":1774872758,"startTime":"0","endTime":"0","summary":"Damora Therapeutics granted new-hire equity awards to President and CEO Jennifer Jarrett on March 30, 2026.Jarrett also received stock options for 1.5 million shares with exercise price $25.50 per share.Vesting terms set 25% of options after one year, then monthly over 36 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief on March 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL8Mv0gX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623317849","title":"Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623317849","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623317849?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:00","pubTimestamp":1774872000,"startTime":"0","endTime":"0","summary":"BOSTON, March  30, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264550/0/en/Damora-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","DMRA","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622800067","title":"Damora Therapeutics files initial beneficial ownership statement; director Michael Landsittel reports no securities beneficially owned","url":"https://stock-news.laohu8.com/highlight/detail?id=2622800067","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622800067?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:50","pubTimestamp":1774475435,"startTime":"0","endTime":"0","summary":"Damora Therapeutics files initial beneficial ownership statement; director Michael Landsittel reports no securities beneficially owned. Damora Therapeutics said director Michael Landsittel filed an initial Form 3 statement of beneficial ownership.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 25, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL2Ghw6d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129559742","title":"Stock Track | Damora Therapeutics Soars 7.88% Intraday on Leadership Shakeup with New CEO and Board Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=1129559742","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129559742?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:44","pubTimestamp":1774273476,"startTime":"0","endTime":"0","summary":"Damora Therapeutics (DMRA) saw its stock price soar 7.88% during intraday trading on Monday, following a significant announcement regarding its executive leadership and board composition.The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123023621","title":"Stock Track | Damora Therapeutics Plunges 8.93% in Pre-Market on Leadership Shakeup","url":"https://stock-news.laohu8.com/highlight/detail?id=1123023621","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123023621?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:18","pubTimestamp":1774268330,"startTime":"0","endTime":"0","summary":"Damora Therapeutics' stock plummeted 8.93% in pre-market trading following news of significant leadership changes at the biotechnology company.The company announced the appointment of Jennifer...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621703222","title":"Damora Therapeutics appoints Jennifer Jarrett as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2621703222","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621703222?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:15","pubTimestamp":1774268141,"startTime":"0","endTime":"0","summary":"Damora Therapeutics (DMRA) announced that its board of directors has appointed Jennifer Jarrett as president and CEO, effective March 30. Jarrett w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/damora-therapeutics-appoints-jennifer-jarrett-as-ceo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/damora-therapeutics-appoints-jennifer-jarrett-as-ceo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","DMRA","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621708772","title":"Press Release: Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2621708772","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621708772?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:00","pubTimestamp":1774267200,"startTime":"0","endTime":"0","summary":"-- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance --. -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors --. -- Peter Harwin named Chairman of the Board of Directors --. BOSTON, March 23, 2026  -- Damora Therapeutics, Inc. , a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that its Board of Directors has appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026. Ms. Jarrett will also serve on the company's Board of Directors.\"We are excited to welcome Jen to Damora as we accelerate our efforts to bring innovative medicines to patients with mutant calreticulin -driven myeloproliferative neoplasm ,\" said Peter Harwin, Chairman of the Board of Directors of Damora Therapeutics. \"With a track record of success in oncology drug development and building and leading high-growth companies, Jen brings a unique se","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","DMRA","BK4232","BK4539","BK4139","LENZ","BK4007","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620827674","title":"Damora Therapeutics FY2025 net loss widened to USD 209.84 million as R&D expenses rose more than tripled to USD 26.88 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620827674","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620827674?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:13","pubTimestamp":1773951199,"startTime":"0","endTime":"0","summary":"Damora Therapeutics FY2025 net loss widened to USD 209.84 million as R&D expenses rose more than tripled to USD 26.88 million. Damora published a full-year earnings press release reporting a net loss of USD 209.84 million.Research and development expenses rose more than tripled to USD 26.88 million, driven by warrant-related costs, higher preclinical and clinical trial-related spending, and increased CMC activities.General and administrative expenses were USD 9.69 million.Cash and cash equivalents were USD 257.62 million as of Dec. 31, 2025, and USD 535 million as of Feb. 28, 2026 following the February 2026 public offering.Management said Sherwin Sattarzadeh expects DMR-001 to remain on track for an IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-genera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL4B5gXv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620276758","title":"Press Release: Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2620276758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620276758?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:10","pubTimestamp":1773951000,"startTime":"0","endTime":"0","summary":"-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 --. -- Strong financial position with approximately $535 million in cash and cash equivalents as of February 28, 2026, expected to fund operations into Phase 3 development of DMR-001 --. BOSTON, March 19, 2026  -- Damora Therapeutics, Inc.   , a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced its operating and financial results for the year ended December 31, 2025, and recent corporate highlights.\"At Damora Therapeutics, we strive to rapidly bring forward best-in-class medicines to dramatically improve the lives of patients with blood disorders. Today, we are well on the path to achieving our goal based on recent progress, including the acquisition of three highly innovative mutant calreticulin  targeted therapies and two oversubscribed financings extending our cash runway into Phase 3 developm","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0267386448.USD","BK4006","LU2237443382.USD","XELA","LU2237443622.USD","BK4590","DMRA","LU2746668461.USD","BK4588","LU0170899867.USD","IE00BKVL7J92.USD","IE00B1BXHZ80.USD","IE00BHPRN162.USD","IE00BZ1G4Q59.USD","LU2237443895.HKD","LU0882574139.USD","LU0971096721.USD","LU1363072403.SGD","BK4139","BK4106","BK4539","IE00BFXG1179.USD","BK4585","LU2237443465.HKD","LU2237443978.SGD","BK4561","LU2237443549.SGD","CMC","BK4007","BK4226","ET","BK4144","LU2746668974.SGD","LENZ","LU0149725797.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618625307","title":"Galecto Inc - Changes Name to Damora Therapeutics; to Trade as \"Dmra\" on Nasdaq March 10, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618625307","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618625307?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:04","pubTimestamp":1773057873,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX10O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GLTO","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618162568","title":"Galecto Inc - Damora to Submit Ind or Cta for Dmr-001 in Mid-2026; Proof-of-Concept Datasets Expected Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2618162568","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618162568?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:04","pubTimestamp":1773057873,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nFWN3ZX10O:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DMRA","BK4139","GLTO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618625435","title":"Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2618625435","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618625435?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:00","pubTimestamp":1773057600,"startTime":"0","endTime":"0","summary":"-- Company will trade on Nasdaq under trading symbol \"DMRA\" effective March 10, 2026 -- -- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251772/0/en/Galecto-Announces-Name-Change-to-Damora-Therapeutics-with-Mission-to-Fundamentally-Redefine-Care-for-Patients-with-Blood-Disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ET","BK4581","BK4144","BK4588","IND","BK4561","BK4585","DMRA","BK4106","GLTO","LENZ","BK4226","XELA","BK4590","CTA","BK4539","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":73,"code":"91000000","status":"200"}]}}